XSPRAY — XSpray Pharma AB (publ) Income Statement
0.000.00%
Last trade - 00:00- SEK1.30bn
- SEK1.22bn
Annual income statement for XSpray Pharma AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 53.5 | 98 | 133 | 182 | 287 |
| Operating Profit | -53.5 | -98 | -133 | -182 | -287 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -52.4 | -96.7 | -132 | -180 | -286 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -52.4 | -96.7 | -132 | -180 | -286 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -52.4 | -96.7 | -132 | -180 | -286 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -52.4 | -96.7 | -132 | -180 | -286 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.98 | -4.92 | -5.4 | -6.68 | -8.62 |
| Dividends per Share |